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Summary
Background Representativeness of antihypertensive drug trials is uncertain, as many trials recruit few or no older 
people. Some trials specifically recruit older participants to address this. Here, we assess the representativeness of 
trials focusing on older people by comparing the rates of serious adverse events in these trials with the rates in trials 
of a general adult population (ie, standard trials), and comparing these findings to the rate of hospitalisations and 
deaths in people with hypertension starting a similar treatment in routine clinical practice.
Methods For this observational study, we identified randomised controlled trials (phase 2/3, 3, or 4) of renin-
angiotensin-aldosterone system (RAAS) drugs for hypertension registered from 1999 onwards with ClinicalTrials.gov. 
Serious adverse events are routinely included in trial reports and are predominantly accounted for by all-cause 
hospitalisations and deaths. We compared serious adverse event rates in older-people trials (minimum inclusion age 
≥60 years) and standard trials (minimum inclusion age <60 years) using Poisson regression models adjusted for trial 
characteristics (drug type, comparison type, phase, and outcome type). We identified a community cohort of 
56 036 adults with hypertension commencing similar drugs to obtain an expected rate of emergency or urgent 
hospitalisations or deaths, and compared this rate to observed serious adverse event rates in each trial, adjusted for 
age and sex. For standard trials and for older-people trials, we calculated the standardised ratio of the expected to the 
observed rate of serious adverse events using Poisson regression models.
Findings We included 110 trials, of which 11 (10%) were older-people trials and 99 (90%) were standard trials. Older-
people trials had a higher rate of serious adverse events than did standard trials (median events per person per 
year 0·18 [IQR 0·12–0·29] vs 0·11 [0·08–0·18]; adjusted incidence rate ratio 1·76 [95% CI 1·01–3·03]). The 
hospitalisation and death rate in the community for those taking RAAS antihypertensives was much greater than the 
rate of serious adverse events reported in standard trials (standardised ratio [SR] 4·23, 95% CI 3·51–5·09) and older-
people trials (4·76, 2·89–7·86), adjusting for age and sex. The magnitude of risk increase for serious adverse events 
in community patients taking RAAS did not differ when comparing older-people and standard trials (ratio of SRs 1·13, 
95% CI 0·66–1·92).
Interpretation Trials report substantially fewer serious adverse events than expected from rates of hospitalisations and 
deaths among similar-aged people receiving equivalent treatments in the community. Serious adverse event rates 
might be a useful metric to assess trial representativeness. Clinicians should be cautious when applying trial 
recommendations to older people, even when trials focus on older participants.
Funding Wellcome Trust, Medical Research Council.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Hypertension is a common and important modifiable 
risk factor for major cardiovascular disease, and is 
associated with age, with more than 75% of people older 
than 80 years diagnosed with hypertension.1 There is 
uncertainty, however, about how hypertension should 
best be managed in older people.2 The risk of cardio­
vascular disease associated with hypertension might 
reduce as people age,3 particularly in people living with 
frailty.4 Furthermore, antihypertensive treatment presents 
a range of potential risks that might disproportionately 
affect older people.
Although randomised controlled trials provide the 
least­biased estimates of treatment efficacy, there are 
concerns that trial participants are often not 
representative of people treated for hypertension in 
routine clinical practice.5 Specifically, older people are 
often excluded from trials.6 This can occur directly, 
through age­based exclusion criteria, or indirectly, 
through other exclusion criteria that disproportionately 
Lancet Healthy Longev 2021; 
2: e398–406
Published Online 
June 10, 2021 
https://doi.org/10.1016/
S2666-7568(21)00092-1
See Comment page e385
*Joint senior authors
Public Health 
(D A McAllister MD, 
J P Renton MPH) and General 
Practice and Primary Care 
(P Hanlon MSc, N Corcoran MSc, 
G Rughani MBChB, 
Prof F S Mair MD), Institute of 
Health and Wellbeing, 
University of Glasgow, 
Glasgow, UK; Department of 
Non-communicable Disease 
Epidemiology, London School 
of Hygiene & Tropical Medicine, 
London, UK (A S V Shah PhD); 
Usher Institute for Population 
Health Sciences, University of 
Edinburgh, Edinburgh, UK 
(Prof B Guthrie PhD)
Correspondence to: 
Dr David McAllister, Public 
Health, Institute of Health and 
Wellbeing, University of Glasgow, 




e399 www.thelancet.com/healthy-longevity   Vol 2   July 2021
exclude older people (eg, comorbidity or co­prescribing), 
as well as through the trial recruitment process (eg, 
through increased demands of participating in a trial, or 
patient or clinician preferences).6,7 To address this 
problem and provide evidence to guide treatments for 
older people, some trials have focused explicitly on older 
people.8,9 However, such trials often only enrol a fraction 
of those invited to participate.10 Consequently, it remains 
unclear whether conducting trials specifically focused on 
older people is sufficient to overcome the difficulties in 
applying trial evidence to older people encountered in 
routine clinical practice.
Older people have a greater risk of adverse health 
outcomes in routine care settings and in trials.11 This is 
likely to be driven by characteristics such as frailty, 
multimorbidity (increasing the risk of drug–disease 
interactions), polypharmacy (increasing the risk of 
drug–drug interactions), and decreased kidney and liver 
function. All these characteristics are more common in 
older age, associated with poor health outcomes, and 
often under­represented within trials.12–16
Previous studies assessing trial representativeness have 
tended to apply trial exclusion criteria to population 
samples derived from routine health­care data or disease 
registries, concluding that many people living with long­
term conditions would be ineligible for trials.5,6,10,17 
However, such an approach does not directly assess the 
health outcomes in trial participants compared with those 
Research in context
Evidence before this study
We searched MEDLINE from inception to Nov 5, 2020, without 
language restrictions, using the terms “hypertension” and 
“trials”, and (“representative*” or “serious adverse events”) for 
studies assessing representativeness of hypertension trial 
populations or assessing the rates of serious adverse events in 
hypertension trials. Four studies, including 24 different trials, 
assessed the representativeness of hypertension trials by 
applying trial exclusion criteria to people with hypertension in 
routine clinical practice. The proportion of people who were 
ineligible for trials was between 50% and 100% in most cases. 
This was true of trials specifically focusing on older adults 
(eg, the HYVET, SPRINT and OPTiMISE trials) in which 
polypharmacy, multimorbidity, and frailty were associated with 
ineligibility. This suggests that trial participants are likely to be 
healthier overall than people treated in the community. Previous 
studies have not directly compared health-related outcomes of 
trial participants with real-world populations. Older adults have 
been shown to have higher rates, and a greater diversity, of 
adverse events in the trial setting. However, we did not identify 
any previous studies that systematically assessed rates of serious 
adverse events in hypertension trials, that compared serious 
adverse events in trials focusing on older people with other 
trials, or that compared serious adverse events in the trial 
population with similar events in community populations.
Added value of this study
After systematically identifying hypertension trials of drugs 
acting on the renin-angiotensin-aldosterone system, we 
showed that trials focusing on older people had a significantly 
higher rate of serious adverse events than comparator trials 
that did not focus specifically on older people (ie, standard 
trials). As would be expected, this suggests that trials focusing 
on older people recruited people with a greater risk of adverse 
health outcomes than trials including all ages. However, the 
rate of all-cause hospitalisations and deaths (which, by 
definition, would be serious adverse events in trial populations) 
among people with hypertension treated in the community 
was on average four times higher than the serious adverse 
event rate in the trials, after adjusting for age and sex. 
This difference in rates was similar for standard trials and trials 
focusing on older people. Therefore, despite having a higher 
risk of serious adverse events than in standard trials, people 
included in hypertension trials focused on older people have a 
considerably lower incidence of adverse health outcomes than 
people of a similar age receiving similar treatment in the 
community. This shows that there are clinically meaningful 
differences between trial populations and people treated for 
hypertension in the community. Furthermore, where serious 
adverse event rates in trials are lower than expected, this should 
prompt careful consideration of trial exclusion criteria and 
population characteristics when assessing representativeness 
and applicability.
Implications of all the available evidence
Our findings show that people in hypertension trials experience 
substantially lower rates of adverse health outcomes than 
people with hypertension treated with similar drugs in the 
community. This adds weight to the body of evidence showing 
that hypertension trials are under-representative of their target 
populations. However, our findings also add nuance to this 
notion, as trials focusing on older people have a significantly 
higher rate of serious adverse events than do standard trials. 
Therefore, trials focusing on older people do, at least in part, 
reflect the increased risk of adverse outcomes seen in older 
populations. Trials focusing on older people therefore have an 
important role in informing treatment decisions in older 
people, but should be viewed with caution as, like standard 
trials, they are not representative of community populations. 
Our findings also indicate that serious adverse event rates 
should be considered as a novel metric with which to assess the 
representativeness of trial populations, through comparison 
with the incidence of similar events in routine clinical care. Such 
an approach could facilitate more direct quantification of the 
consequences of trial under-representativeness; however, this 
would require consistent and complete recording and reporting 
of serious adverse events as well as reliable estimates of event 
rates in the community.
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receiving routine care. An alternative approach is to 
analyse serious adverse events. Serious adverse events in a 
trial setting are events that are either life threatening, lead 
to death, cause or prolong hospitalisation, result in serious 
or lasting impairment or disability, or cause a birth 
defect.18 Among serious adverse events, hospitalisations 
and deaths are the most common. Regulatory bodies 
require that trial sponsors record and report all serious 
adverse events,19 with recording also part of the 
CONSORT statement for the publication of trial findings.20 
Importantly, serious adverse events are required to be 
reported irrespective of the suspected cause, for both 
treatment and control arms. Therefore, serious adverse 
events should provide a reliable measure of the rate of 
adverse health outcomes (particularly resulting in 
hospitalisation and death) within a trial population. 
Indeed, if a trial were perfectly representative, we would 
expect the serious adverse event rate of that trial to be 
similar to hospitalisation and death rates among the target 
population with the same condition, to whom the trial 
results are intended to apply. We would also expect trials 
involving older people to have higher serious adverse 
event rates than trials for the same indication recruiting a 
more general adult population.
The aim of this Article is to compare the rates of serious 
adverse events in trials of older people with the rates 
found in trials not focusing specifically on older people 
(which we will call standard trials), and to compare rates 
of serious adverse events in each trial to the rate of 
serious adverse events (ie, hospitalisations and deaths) in 
people with hypertension starting a similar treatment in 
routine clinical practice, adjusting for age and sex. As an 
exemplar, here we focus on drugs to treat hypertension 
acting on the renin­angiotensin­aldosterone system 
(RAAS). RAAS drugs were chosen since they are 
commonly used to treat hypertension, including in older 
people. There are also concerns that older people are 
under­represented in RAAS trials.5,17,21 Furthermore, 
associated risks of RAAS drugs such as renal dysfunction, 
orthostatic hypotension, syncope, and polypharmacy are 
likely to be greater in older people.22
Methods
Study design and participants
This observational study compares serious adverse 
event rates in registered randomised controlled trials 
of RAAS drugs to treat hypertension with hospitalisation 
and death rates in a community sample of adults with 
hypertension who were initiated on RAAS drugs. Trials 
were identified from an extraction on Aug 1, 2017, of 
all clinical trials registered at ClinicalTrials.gov (a registry 
of clinical trials from across the world managed by 
the US National Institutes of Health), to which we 
had applied the WHO Anatomic Therapeutic Chemical 
(ATC) drug classes for all interventions.12 To be eligible, 
trials had to be registered from 1999 onwards, be phase 2/3, 
3, or 4, have eligibility criteria published in English, and be 
evaluating RAAS drugs for the treatment of hypertension. 
We included trials in two stages. First, we identified all 
trials with a minimum inclusion age of 60 years or older 
and defined these as trials of older people. We reviewed 
these to identify the drugs and indications for which such 
trials were commonly undertaken. Second, we obtained, as 
a comparator group, all trials for the same indications 
and drugs with a minimum inclusion age of less than 
60 years (ie, standard trials). We included single­centre or 
multicentre trials undertaken in any country, with 
published or unpublished results.
The community comparison sample was identified 
using the Secure Anonymised Information Linkage 
(SAIL) databank. SAIL collects routine health­care 
data (including primary care diagnostic codes and 
prescriptions, with linked hospital and mortality data) 
from participating practices in Wales (covering approxi­
mately 70% of the Welsh population). SAIL participants 
are representative of the Welsh population in terms 
of age, sex, and socioeconomic status. We identified adult 
participants with a previous diag nostic code for 
hypertension in primary care who were prescribed a 
RAAS drug for the first time between Jan 1, 2011, and 
Dec 31, 2015. We excluded participants who registered 
with a SAIL practice less than 12 months before starting 
treatment with the RAAS drug. We also excluded people 
with any coded myocardial infarction or stroke occurring 
in the 12 months before treatment initiation, as these 
people were unlikely to be receiving the RAAS drug 
solely to treat hypertension and so were likely to have 
higher rates of hospitalisations and deaths.
Measures
We extracted the following information on included 
trials from ClinicalTrials.gov, clinical trial reports, and 
published papers: baseline characteristics of the trial 
participants (age, sex, body­mass index), number of 
trial participants, trial phase, trial drug, comparison 
treatment, outcomes, follow­up times, and the occurrence 
of serious adverse events (total number of events). We 
also recorded whether the trial outcome was a hard 
outcome (ie, a clinical endpoint such as major adverse 
cardiovascular event or mortality) or soft outcome (ie, a 
surrogate marker such as change in blood pressure). For 
trials with hard outcomes, the number of clinical 
endpoint events was added to the number of serious 
adverse events before comparing event rates with the 
community population, as both endpoints and serious 
adverse events are likely to represent hospitalisation or 
deaths. We included serious adverse events and clinical 
endpoints from both the treatment and control arms of 
each trial, as most serious adverse events in the trial 
setting are not specifically related to the trial treatment.23 
To confirm this, we also compared serious adverse event 
rates in the treatment and placebo arms.
For each participant in the community sample, we 
identified age and sex. We then calculated the number of 
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all­cause emergency or urgent hospitalisations (excluding 
elective admissions) or deaths occurring over 3 years of 
follow­up. Participants were censored at death or if they 
deregistered from a participating practice within the 
3­year period.
Statistical analysis
Our first analysis compared the serious adverse event 
rate in trials of older people with the rate in standard 
trials, adjusting for trial characteristics. We modelled 
serious adverse events on older­people trial status using 
hierarchical Poisson regression models (with random 
intercept and Poisson likelihood), both unadjusted 
(offset by estimated person­time, which was calculated 
as follow­up × (number of participants – 0·5 × number of 
serious adverse events)) and adjusted for direct renin 
inhibitor trial (yes or no), comparison type (placebo, 
different ATC class to three­character class [eg, an RAAS 
drug vs a calcium channel blocker], or different ATC class 
to five­character class [eg, an angiotensin II receptor 
blocker vs an angiotensin­converting enzyme inhibitor]), 
phase (3 or 4), and outcome type (hard or soft). The 
adjusted model was the prespecified primary analysis 
and was used to calculate incidence rate ratios (IRRs). 
Models were fitted using the rstanarm package to allow 
fitting of the random intercept for the trials and 
calculation of 95% credible intervals (CrIs).
We also used Poisson regression to model the age­specific 
and sex­specific rate of emergency or urgent hospital 
admissions or death in the 3 years following initiation of 
RAAS drugs in SAIL. This model fitted the data well 
(appendix pp 1–4), and the covariates and variance–
covariance matrix were exported from the SAIL secure 
platform to allow us to calculate the expected number of 
hospitalisations and deaths for each trial population, as a 
proxy for serious adverse events. We then calculated the 
ratio of expected­to­observed serious adverse events. We 
used the truncated normal distribution to estimate the age 
distribution for each trial based on the reported mean age, 
as well as any age cutoffs used as exclusion criteria. In a 
previous analysis of individual participant data (including 
trials with the same eligibility criteria as trials included in 
the current sample), the truncated normal distribution was 
found to accurately represent the age distribution of trials 
in this context.12 We generated 95% CrIs for the expected­to­
observed ratio for each trial as follows. We obtained 
10 000 samples of the intercept, age, and sex coefficients by 
sampling from a multivariate normal distribution where 
the parameters were the point estimates and variance–
covariance matrix for the SAIL Poisson regression models. 
For each sample, we applied the coefficients to the age­sex 
distribution of each trial to obtain 10 000 samples from the 
distribution of the expected count. We then divided each of 
these by each of 10 000 samples from a Poisson distribu tion 
(where the parameter was the observed count) to obtain 
10 000 samples representing the uncertainty distribution 
for the expected­to­observed ratio, which we summarised 
by the mean and 2·5th and 97·5th centiles.
We obtained the standardised ratio (SR) of 
hospitalisations and deaths in the community and serious 
adverse events in the trials by treating the log of the 
expected count (which was obtained by applying 
the SAIL­derived age­sex­specific rates to the age­sex 
distribution of each trial) as an offset term in the 
previously described hierarchical Poisson regression 
models. The first model compared standard and older­
people trials. The second model further adjusted for trial 
characteristics.
We did three sets of sensitivity analyses. First, in view 
of the small number of older­people trials, we reran 
Figure 1: Trial inclusion
ATC=Anatomic Therapeutic Chemical. RAAS=renin-angiotensin-aldosterone system. *The entry for the specific 
field in ClincialTrials.gov for the minimum age was missing. The full text of the trial registration was then reviewed 
to identify if the trial was targeted specifically at older participants. †All RAAS drugs were permitted for the 
selection of eligible older-people trials. Only drugs that were studied in one or more of the older-people trials 
(aliskiren, irbesartan, olmesartan, telmisartan, or valsartan) were selected for the comparator group of the 
standard trials. ‡Within-drug comparisons refers to trials where all arms included the same drug (eg, trials of 
different dosages or regimens). Within-class comparisons refers to trials where all arms included drugs with the 
same five-character ATC class (eg, drugs in WHO ATC class C09CA are all angiotensin II receptor blockers). 
§Excluded because none of the older-people trials were phase 2/3.
Stage 1: older-people trials
51 with minimum age ≥60 years
38 considered hypertension plus 
other conditions
11 considered hypertension plus 
other conditions
1 featured within-class 
comparisons‡
14 excluded
13 featured within-drug or 
within-class comparisons‡
1 phase 2/3§
1913 did not involve the same RAAS 
drugs identified in the 
older- people trials†
Stage 2: comparator group
2075 with minimum age <60 years
20 with missing age classified 
after full-text review*
13 treated hypertension as sole 
condition with RAAS
131 treated hypertension as sole 
condition with RAAS
12 investigated for serious adverse 
event data
117 investigated for serious 
adverse event data
11 included in analyses 99 included in analyses
142 used same RAAS drugs as in 
older-people trials
2126 trials identified on ClinicalTrials.gov
1 had no data on serious adverse 
events
18 had no data on serious 
adverse events
For more on the rstanarm 
package see https://mc-stan.
org/rstanarm
See Online for appendix
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the regression models excluding each trial in turn 
to examine the sensitivity of the findings to trial 
characteristics. The second sensitivity analysis explored 
the impact of possible misclassification of the indication 
for RAAS treatment within the community cohort. For 
this, in addition to excluding participants with recent 
myocardial infarction or stroke (as done in the main 
analysis), we also excluded any participant with a 
previous diagnosis of diabetes, heart failure, or chronic 
kidney disease. We then repeated all analyses comparing 
trials with the community cohort. Finally, as the trial 
follow­up periods were shorter than the observation time 
of the community cohort, we repeated all analyses 
limiting follow­up of the community sample to the first 
90 days following initial prescription (to match the 
median follow­up in the trials) and analysing first event 
only (ie, censoring at 90 days, first hospitalisation, or 
death, whichever happened first).
All analyses were done using R (version 3.6.1).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
We included 110 trials, of which 11 (10%) were trials in 
older people and 99 (90%) were standard trials that did 
not focus specifically on older people (figure 1; table). 
Trial characteristics for all included trials, such as NCT 
number, trial setting, and number of participants, are 
available online. The median number of serious adverse 
events per trial was 7·5 (IQR 3·0–14·0). The median 
rate of serious adverse events per person per year 
was 0·18 (0·12–0·29) in the older­people trials and 0·11 
(0·08–0·18) in the standard trials. These serious 
adverse event rates refer to the whole trial population, 
as rates were similar between treatment and control 
arms in any placebo­controlled trials (IRR 0·81, 95% CrI 
0·59–1·08).
Before adjusting for trial characteristics, the IRR for 
older­people versus standard trials was 1·70 (95% CrI 
1·07–2·77). After adjusting for trial drug, type of 
comparison, trial phase, and type of outcome, older­
people trials had a higher incidence of serious adverse 
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66 (67%) 8 (73%) ··
Renin inhibitor 33 (33%) 3 (27%) ··
Comparison
Placebo 22 (22%) 1 (9%) ··
Drug of different class 77 (78%) 10 (91%) ··
Phase
3 67 (68%) 5 (45%) ··
4 32 (32%) 6 (55%) ··
Trial endpoint
Hard 1 (1%) 2 (18%) ··
Soft 98 (99%) 9 (82%) ··





Trial follow-up, days 63 (56–98) 98 
(56–252)
··
Data are median (IQR), mean (SD), n (%), or %. Data for each trial are available 
online, including data on baseline blood pressure (four [36%] older-people trials 
and 46 [46%] standard trials), comorbidity status (three [27%] older-people trials 
and 37 [37%] standard trials), and ethnicity (two [18%] older-people trials and 
39 [39%] standard trials). These are not summarised in this table due to the high 
proportion of missing data. SAIL=Secure Anonymised Information Linkage.
Table: Summary of included trials
For trial data see https://github.
com/dmcalli2/adverse_events_
older_people
Figure 2: Inclusion and analysis of SAIL participants for community 
comparison






or stroke, or recent 
registrations
Mean observation time 2·8 years
(SD 0·55) per person
26 173 events (hospitalisation or death)







111 653 adult SAIL participants with initial 
prescription for RAAS drug in 2011–15 
70 083 with a diagnostic code of hypertension 
at any time before prescription 
68 336 with no myocardial infarction or stroke 
in past 12 months
56 036 included with any previous 
hypertension code who had been 
registered for at least 12 months
28 167 (50·3%) female
27 869 (49·7%) male
41 570 without hypertension
1747 with recent myocardial 
infarction or stroke
12 300 recently registered with SAIL 
practice
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Our SAIL community sample consisted of 
56 036 individuals starting RAAS drugs in routine clinical 
practice, who experienced 26 173 emergency hospital­
isations or deaths over the 3­year follow­up (figure 2; 
table). When applying community all­cause non­elective 
hospitalisation and death rates to the age­sex distribution 
of each trial, the observed rates were consistently lower 
than the age­adjusted and sex­adjusted expected rates 
(figure 3).
The rate of serious adverse events was lower than 
the expected rate of hospitalisations and deaths given 
the age­sex distribution of trial participants for all but 
one of the trials (with this exception being a standard 
trial; figure 4). There was considerable heterogeneity in 
the calculated ratios within both the older­people trials 
and the standard trials. However, across all trials, the 
reported rate of serious adverse events was considerably 
lower than would be expected if the trials were 
representative of people with hypertension taking 
RAAS drugs in the community. The SR was 4·23 
(95% CI 3·51–5·09) for standard trials and 4·76 
(2·89–7·86) for older­people trials, indicating that 
hospitalisations and deaths occurred more than 
four times more frequently among people taking 
RAAS drugs in the community than serious adverse 
events occurred in trials. The magnitude of risk increase 
for serious adverse events in community patients taking 
RAAS did not differ when comparing older­people and 
standard trials (ratio of SRs 1·13, 95% CI 0·66–1·92). 
The results were similar after adjusting for trial drug, 
type of comparison, trial phase, and type of outcome 
(adjusted SR 4·53 [2·84–7·37] for standard trials 
and 4·88 [2·34–10·48] for older­people trials; ratio of 
SRs 1·08 [0·58–2·02]).
In the first sensitivity analysis, the effect estimates 
were similar when leaving out each trial in turn. In the 
second sensitivity analysis, the difference in serious 
adverse events rates between trials and the community 
was similar after further excluding people with diabetes, 
heart failure, or chronic kidney disease from the 
community sample to minimise the risk of misclassifi­
cation of the indication for RAAS treatment (appendix 
pp 5–7). In the final sensitivity analysis, when limiting 
follow­up of the community sample to 90 days to match 
median follow­up time of trials, the difference in rates 
between trials and community remained similar 
(appendix pp 8–10).
Discussion
In this analysis of trials of RAAS drugs for hypertension, 
trials specifically recruiting older people (minimum 
inclusion age ≥60 years, mean age >70 years) had a 
significantly higher incidence of serious adverse events 
than did standard trials, after adjusting for trial charac­
teristics. This suggests that trials of older people recruit 
participants with a higher baseline risk of adverse health 
outcomes. Nonetheless, both in trials of older people and 
standard trials, the rate of serious adverse events was 
substantially lower than the expected rate based on the 
incidence of non­elective hospitalisation and death—
which would be classed as serious adverse events in all 
trials—in people with hypertension being treated in the 
community. The difference in rates was large, with rates 
of hospitalisations and deaths in the community on 
average four times greater than the rate of serious adverse 
events in the trials. This suggests that, even accounting 
for age and sex, participants in hypertension trials and 
people with hypertension in the community are very 
different populations. These differences between trial 
and community populations might reflect differences in 
geographical or health­care settings of trials and the 
community cohort in Wales (although hospitalisation 
rates in the UK are comparable with other countries 
within the Organisation for Economic Co­operation and 
Development, suggesting that the rates observed in the 
community sample used in this study are similar to other 
settings), as well as demographic and clinical differences 
between the trial and community populations. These 
differences, in part driven by trial exclusion criteria, might 
include comorbidity and underlying health status, as well 
as other factors such as ethnicity, socioeconomic status, 
hypertension severity, health­care utilisation, and 
medication adherence. Of note, many of these factors 
were not reported in the included trials.
Figure 3: Observed versus expected serious adverse events per trial
The observed rate of serious adverse events per trial is plotted at the mean age for the trial, with the sample size for 
each trial indicated by the size of the point. The expected number of hospitalisations and deaths for each trial, 
obtained by applying community all-cause non-elective hospitalisation and death rates to the age-sex distribution 
of each trial, is shown by the purple points. Each trial point has a community comparison point which is its pair, but 
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The difference in serious adverse event rates between 
trial and community populations was similar for older­
people trials and for standard trials. This does not 
necessarily mean trial findings are inapplicable to 
community patients. Relative treatment benefits estimated 
in trials will often be applicable even where there are 
differences between trial and target populations,24 but net 
benefit can still vary because adverse events are more 
common in community populations, and optimal choice 
of drug might be affected by comorbidity and 
co­prescribing, which are more likely in the community. 
This suggests that clinical guideline developers are correct 
to be cautious when applying trial evidence to community 
populations, particularly to older, multimorbid, or frailer 
populations, and that this caution remains justified even 
when trials are deliberately targeted at older people.
While these findings suggest that trials are under­
representative in terms of underlying risk of adverse 
health outcomes, there are two alternative explanations 
that could also contribute to the observed differences 
between trials and the community sample. First, trials 
might under­report the true incidence of serious adverse 
events. Despite reporting guidelines,20 there is 
inconsistency in how serious adverse events are 
reported.25 However, trial­recorded serious adverse events 
include events other than emergency hospitalisations or 
death, meaning that the incidence of serious adverse 
events in trials would be expected to be higher than the 
community events examined. Second, our community 
sample might include people taking RAAS for other 
indications, for whom the risk of hospitalisations and 
deaths might therefore be higher. For this reason, the 
primary analysis excluded people with recent myocardial 
infarction or stroke, and the sensitivity analysis excluded 
people with a history of diabetes, chronic kidney disease, 
or heart failure, with consistent findings across all 
analyses. Nonetheless, we cannot be certain about the 
true indication for starting RAAS drugs from routine 
data alone. Both under­reporting of serious adverse 
events in trials and misclassification of the community 
comparison might bias our estimation of the difference 
between trials and community samples. However, the 
difference between trial and community populations was 
large, and it is likely that the observed lower rates of 
serious adverse events in trial populations is accurate.
Our findings have implications for interpreting trials 
that specifically recruit older people. Such trials are likely 
to be helpful in informing treatment decisions as they 
more successfully recruit older people who are at higher 
risk of serious adverse events than do standard trials, thus 
capturing some of the increased risk of this population. 
However, concerns about trial representativeness are 
still well founded, as suggested by the observed difference 
between serious adverse events in trials and hospital­
isation and death rates in the community. We observed 
that this difference was similar for both trials of older 
people and standard trials, suggesting that they were 
Figure 4: Ratio of expected-to-observed serious adverse event count
Each point (with 95% CI) shows the ratio of expected all-cause non-elective hospitalisations or deaths (given the 
estimated age-sex distribution of each trial) to the observed serious adverse event count in each trial. 
Four standard trials that reported no serious adverse events are excluded from this figure as the ratio would have 
been infinite. Seven standard trials that reported only one serious adverse event, and thus had ratios greater 
than 50, are also excluded. A further 22 trials were excluded as they reported insufficient data on the age-sex 
distribution to calculate the expected rate.
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similarly under­representative. This suggests that trials 
focusing on older people present only part of the solution 
to informing treatment decisions for older people, 
particularly those at higher risk of adverse health 
outcomes, such as people living with frailty.
The higher rate of hospitalisations and deaths in the 
community population has some important implications 
for managing hypertension in older people. First, this 
finding is likely to reflect a higher prevalence and severity 
of frailty in community populations compared with 
trials, which might modify the relationship between 
hypertension and cardiovascular risk.4 We previously 
showed, in an individual­level participant data analysis, 
that frailty is associated with increased risk of serious 
adverse events in trials.13 Furthermore, frailty 
in participants in cardiovascular trials is associated 
with adverse cardiovascular outcomes independently of 
traditional risk factors.26 While frailty has been shown to 
be present in participants of trials for hypertension in 
older people,8,9 frailty in these trial participants is thought 
to be less severe than frailty in people in the community.2 
People living with severe frailty are likely to be excluded 
from clinical trials; however, such individuals are 
commonly prescribed the trial medications in routine 
clinical practice, often in the context of polypharmacy. 
The applicability of trial evidence to a broader population, 
even in the case of trials recruiting older people, needs 
careful consideration. It is also likely that trial evidence is 
insufficient to inform treatment decisions in some 
patient groups, such as people living with severe frailty.
Second, the difference in serious adverse events 
between trial and community populations could affect 
the net benefit of treatment when used in routine clinical 
practice.27 For example, higher competing mortality risks 
in the community might mean that benefits in terms of 
absolute treatment effects (based on trial participants) 
are overestimated.28 Also, if drug­related serious adverse 
events were more common in the community (eg, among 
people living with frailty), this could reduce the net 
benefit of treatment.29,30 For example, even if drugs reduce 
cardiovascular outcomes, net benefit might decrease if 
serious adverse event rates increase rapidly with age. 
Quantifying net benefit would require analysis of 
differential treatment effectiveness and also treatment­
related serious adverse events, neither of which are 
possible with the data from this study. However, our 
findings do indicate that clinicians and guideline 
developers should be cautious when applying trial 
estimates of benefit to the wider population.
Strengths of this study include a systematic identification 
of registered trials. With our search of a trial register, as 
well as a manual search of clinical study reports, we were 
able to include both published and unpublished trials, 
limiting publication bias. Restricting our search to 
ClincalTrials.gov might have resulted in a small proportion 
of studies not being included in our investigation. 
However, ClinicalTrials.gov is the largest international 
trial registry and trial preregistration is required both for 
publication in high­impact journals and for trial results to 
qualify as evidence for regulatory agencies such as the 
US Food and Drug Administration.19 Moreover, it provided 
a single sampling frame from which we could draw all 
older­people and standard trials. Limiting our search to 
trials started from 1999 onwards ensured that trials were 
conducted in a similar time period to the community 
comparison, and during a period in which trial registration 
has become increasingly commonplace; however, this will 
have led to the exclusion of earlier trials, including some 
of commonly prescribed RAAS drugs such as angiotensin­
converting enzyme inhibitors. The systematic comparison 
of serious adverse event rates in trials with hospitalisation 
and death rates in the community for people with 
hypertension is novel and builds upon previous studies of 
trial representativeness by comparing actual health­related 
outcomes rather than exclusion criteria. Nonetheless, 
comparing serious adverse events to hospitalisations and 
deaths is not an exact like­for­like comparison. Serious 
adverse events are based on a broader definition that 
includes events perceived to be life threatening as well as 
events leading to impairment or disability, which might 
not necessarily result in hospitalisation. However, 
hospitalisations and deaths are, by definition, serious 
adverse events, and so any bias is very likely towards 
underestimating the difference between trial and 
community rates. Trial data were reported inconsistently, 
and for some trials we had to estimate the observation 
time in the trial (based on follow­up length and the serious 
adverse event rate). Also, as we have highlighted above, we 
were not able to verify the indication for RAAS drugs in 
the community. While we excluded participants with 
recent events that would be alternative indications, there 
might be some participants in our sample who were 
prescribed RAAS drugs for reasons other than 
hypertension. Finally, this study focused on RAAS drugs 
for hypertension, and the findings might not necessarily 
be generalisable to other drugs or indications, particularly 
as serious adverse event rates for angiotensin receptor 
blockers might be lower than for other antihypertensives.29
In conclusion, our study shows that participants in 
hypertension trials experience substantially lower rates 
of serious adverse health outcomes than do people with 
hypertension treated with similar drugs in the 
community. Our work suggests that assessment of the 
rate of serious adverse events in trials, when compared 
with the expected rate from representative target 
populations, could be a useful metric of trial 
representativeness. Our findings also show that the 
problem of under­representativeness is not sufficiently 
resolved by recruiting older people to trials, as both older­
people trials and standard trials were under­representative 
in terms of serious adverse events. This observation 
emphasises the need for developing approaches to trial 
design and execution that enable older people living with 
frailty to become trial participants.
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